General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KWKQC
ADC Name
DX126-262
Synonyms
DAC-001; DX126 262; DX126-262; Recombinant anti-HER2 antibody-Tub 114
   Click to Show/Hide
Organization
Hangzhou DAC Biotech Co., Ltd.
Drug Status
Phase 2
Indication
In total 3 Indication(s)
Gastric cancer
Phase 2
Clinical Trial
Oesophageal cancer
Phase 2
Clinical Trial
Breast cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
3.5 to 3.8
Structure
Antibody Name
DX-CHO9
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (HER2)
 Antigen Info 
Payload Name
Tubulysin B analog Tub114
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Mal-PEG10-Ala-Ala-linker
 Linker Info 
Conjugate Type
Random Cysteines
Special Approval(s)
Special approval (NMPA)